CD28 and neoplasm: This concept is supported by work from Textor et al., demonstrating superior anti-tumor activity against neuroblastoma and carcinoma xenografts by CAR-T cells incorporating a CD28 co-stimulatory domain (characterized by stronger activation signals and effector differentiation) compared to those with a 4-1BB domain (associated with longer persistence but more gradual activation) [38].